Streetbeat News

Stock Prices

PRAX

Praxis Precision Medicine (NASDAQ:PRAX) reported Q2 2024 GAAP EPS of $(1.74), beating the estimate of $(2.31). However, sales of $357,000 missed the $870,000 estimate and decreased by 54.29% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:14 am

CCLD

CareCloud expects to further improve profitability and reduce its credit facility balance to zero in the coming months.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:14 am

BIDU

GOOG

MBLY

TSLA

Gary Black, Managing Partner at The Future Fund, expressed skepticism about Tesla's monopoly in the unsupervised L4/L5 autonomy market, highlighting competition from Baidu, Mobileye, and Alphabet's Waymo. Black believes these companies will achieve and receive approval for unsupervised autonomy around the same time as Tesla. He also noted the increasing segmentation between consumer and industrial-strength autonomous vehicles and questioned the evidence supporting Tesla's Full Self-Driving capability.

Portfolio Pulse from Benzinga Neuro

August 13, 2024 | 11:09 am

CIFR

Cipher Mining shares are trading lower following a Q2 revenue miss.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:08 am

CNTA

Centessa Pharmaceuticals (NASDAQ:CNTA) reported a Q2 2024 GAAP EPS of $(0.40), missing the analyst consensus estimate of $(0.39) by 2.56%.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:08 am

MNMD

Mind Medicine (MNMD) reported a Q2 2024 GAAP EPS of $(0.26), beating the estimate of $(0.33). The company has a cash balance of $243.1M and recently closed a public offering of $75M in gross proceeds, which is expected to provide a cash runway into the first half of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:07 am

ZPTA

Zapata Computing Holdings shares are trading higher after the company entered a Cooperative Research and Development Agreement with the US Special Operations Command.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:07 am

BAX

Baxter shares are trading higher following the announcement of a definitive agreement to divest its Vantive Kidney Care segment to Carlyle for $3.8 billion.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:05 am

SRAD

Sportradar Group has raised its fiscal year 2024 revenue outlook to €1.070 billion, up from the prior €1.060 billion, and adjusted EBITDA to at least €204 million, up from €202 million. This represents a 22% year-over-year increase and a 1-percentage point improvement in the full-year growth rate outlook.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:05 am

MRNS

Marinus Pharma (NASDAQ:MRNS) reported Q2 earnings per share (EPS) of $(0.63), missing the analyst estimate of $(0.59). The company also reported sales of $8.06 million, falling short of the $9.49 million estimate. Despite the misses, sales increased by 32.48% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:05 am